logo
Surgeries postponed at Broward Health as financial woes of anesthesiology group deepen

Surgeries postponed at Broward Health as financial woes of anesthesiology group deepen

Yahoo14-02-2025

Elective surgeries at Broward Health's four hospitals were postponed this week as unpaid anesthesiologists walked off the job and financial problems deepened for Anesco, the systemwide anesthesia provider.
Patients with planned operations such as hip replacements and hernia repairs were told their surgeries would be delayed. The hospitals — Broward Health Medical Center in Fort Lauderdale, Broward Health North in Pompano Beach, Broward Health Coral Springs and Broward Health Imperial Point in Fort Lauderdale — lacked anesthesiology staff, using the remaining medical professionals for more urgent surgeries.
Anesco North Broward, a privately owned anesthesia group, has had the exclusive contract to provide anesthesia services at Broward Health hospitals for over 25 years. Most doctors and nurses it employs have non-compete agreements, making it difficult to leave. Most of the professionals have continued to work, despite not being paid, while some nurses and doctors have resigned.
A dozen Anesco doctors and nurses told the South Florida Sun Sentinel recently they hadn't been paid in weeks, some even as much as three months.
Along with staff, Anesco hires contract workers, who also haven't been paid.
Health | Broward Health ends longtime contract with financially troubled anesthesia group
'This is our livelihood,' said a nurse who asked not to be identified out of fear of not being employable. 'We are out thousands of dollars. We provided excellent anesthesia services and we were not paid. But our issues are nothing compared to the amount of people who need the care they may not be able to get. We have to make it known the care you get at Broward Health is lacking because anesthesia services are not adequately being provided.'
Friday is Anesco payday, but CEO Richard Meli told the South Florida Sun Sentinel on Wednesday: 'We are not going to be able to make payroll. It might be like D-day on Friday. Our plan is to sort of plead with our practitioners to keep working for the patient care because that's the biggest issue we care about.'
Broward Health CEO Shane Strum said Thursday that his health system is already working with recruiting firms to hire temporary staff to fill anesthesiology vacancies after Friday because they are anticipating more staff departures. The replacement workers could begin working as soon as Monday.
Because Anesco employees have non-compete agreements, the hospital cannot hire them as Broward Health employees. And because Broward Health has already paid Anesco, the hospital district's position is that they would not provide the back pay either.
After learning that Anesco had not paid its employees, Broward Health terminated the contract on Jan. 28, giving it a 150-day notice through the end of May. Strum would not confirm reports that Broward Health has already hired another provider, Envision, to provide anesthesia services when Anesco leaves after that period.
'Broward Health wouldn't be doing their job if we didn't have a backup plan,' Strum said. 'We are hiring and are 100% prepared for the minute he (Meli) breaches or his doctors walk. His anesthesiologists might not be able to work … but we have other anesthesiologists.'
It is unclear how Anesco plunged into such extreme financial distress; the company's only client for more than 25 years has been Broward Health.
Meli attributes Anesco's financial problems to rising labor costs and conflicts with Broward Health over fees. 'What's happened in the last few years is the cost for anesthesiologists has risen dramatically. And they keep going up and up. …The market for CNAs (certified nurse assitants) and physicians has doubled.' Meli said he asked Broward Health for subsidies, but they weren't enough.
He also said billing problems were caused during Broward Health's transition to a new electronic medical records system. The system is used nationwide by mutiple large hospital systems; Strum says the Broward Health implementation was completed by November.
Strum said Anesco asked Broward Health several times over the last 18 months for supplemental funds. He said Broward Health has given him money each time Anesco asked for it, providing millions in subsidies and even upfronting funds to Anesco through March. 'He is constantly needing more money,' Strum said. Strum said Broward Health would not provide Anesco's professionals back pay, but would hope to hire them in the future, if possible.
Meli and his attorney, David DiPietro, said Anesco wants to work with Broward Health to complete its contract and hopes to avoid filing for bankruptcy.
'We want to work to transition out where the patient continuum care continues and it's a win-win for everybody,' DiPietro said. 'If Broward Health wants a divorce from Anesco, we recognize that. We don't agree with it. We would love to keep doing business with them, but we have to accept reality. We want make sure the continuum care is done and we're compensated for what we're owed.'
In a letter this week to Broward Health, Anesco requested 'a lump-sum buyout of its contract for $6 million.'
Strum said the next few weeks may be 'bumpy' as the health system and Anesco cut ties.
'Broward Health is built to last,' he said. 'We've been in these situations before. We're actually several steps ahead on our planning and when it does happen, we will be prepared to do everything that we need to.'
South Florida Sun Sentinel health reporter Cindy Goodman can be reached at cgoodman@sunsentinel.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

Yahoo

time3 hours ago

  • Yahoo

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

VA Marks Benefits Milestone For Veterans
VA Marks Benefits Milestone For Veterans

Miami Herald

time5 hours ago

  • Miami Herald

VA Marks Benefits Milestone For Veterans

The Department of Veterans Affairs (VA) has announced that its mobile app has now accumulated more than 3 million downloads since its launch in 2021. The Health and Benefits app, which has 1.4 million active users, provides veterans access to information on health care and benefits. It allows users to refill and track VA prescriptions, review appointments, review claims and appeals status, submit evidence for claims and appeals, review VA payment and direct deposit information, locate the closest VA facilities, access the Veterans Crisis Line and show proof of Veteran status. VA Acting Assistant Secretary for Information and Technology and Acting Chief Information Officer Eddie Pool said: "VA's Health and Benefits app gives Veterans fast and convenient access to a host of important information, from appointments to prescriptions and benefits. We encourage all VA-enrolled Veterans to stay connected and informed by downloading the app." This story will be updated. Related Articles How Veteran's Benefits Are Impacted by Trump's Tax Bill: What to KnowHegseth Joins Veterans in Normandy to Mark 81st Anniversary of D-DayList of Cities Hosting 50501 Protests on June 6Harvey Milk Navy Ship To Be Renamed-Vets Call It 'Insult to LGBTQ Troops' 2025 NEWSWEEK DIGITAL LLC.

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

Yahoo

time7 hours ago

  • Yahoo

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized drug delivery technologies for surgical infection prevention. The below report explores the company's breakthrough PLEX platform technology, its upcoming topline phase 3 data, and potential implications for transforming surgical care practices in the multi-billion dollar surgical site infection prevention market. This report contains sponsored content, please see refer to the disclaimers and disclosures included at the end of this report. Executive Summary The surgical site infection (SSI) prevention landscape stands at a potential inflection point as PolyPid Ltd. prepares to announce topline results from its pivotal SHIELD II Phase 3 trial by the end of Q2 2025. The company's D-PLEX100 represents a paradigm shift in infection prevention, utilizing novel polymer-lipid encapsulation matrix (PLEX) technology to deliver sustained antibiotic release directly at surgical sites for 30 days. With SSIs affecting up to 30% of colorectal surgeries and imposing substantial healthcare costs estimated at $10 billion annually in the US and EU, successful development of D-PLEX100 could address a critical unmet medical need. The FDA's assignment of Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations underscores the regulatory recognition of this approach's potential Critical Challenge of Surgical Site Infections Surgical site infections remain one of healthcare's most persistent challenges, representing 20% of all healthcare-associated infections in US hospitals. Despite advances in surgical techniques and prophylactic protocols, SSI rates in high-risk procedures like colorectal surgery can reach 30%, leading to extended hospital stays of 7-11 additional days and mortality risk increases of 2-11 fold. The economic burden is staggering, with direct costs averaging $11,000-26,000 per infection and total annual costs reaching approximately $10 billion in the US alone. Current prevention strategies rely primarily on systemic antibiotic prophylaxis administered intravenously 30-60 minutes before surgery. However, this approach faces fundamental limitations. Surgical incisions disrupt local blood flow, significantly limiting antibiotic penetration to the precise site where infections occur. Moreover, systemic administration exposes patients to higher drug concentrations throughout the body, potentially increasing toxicity risks and contributing to antimicrobial resistance development. PLEX Technology: A Novel Approach to Localized Drug Delivery PolyPid's proprietary PLEX technology represents a sophisticated advancement in controlled drug delivery systems. The platform creates thousands of alternating layers of biocompatible polymers and lipids that physically embed active pharmaceutical ingredients. As these outer layers gradually disintegrate upon exposure to body fluids, they enable precise, predetermined drug release rates spanning several days to months. For D-PLEX100, this technology pairs with doxycycline, a broad-spectrum antibiotic effective against both gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. The formulation achieves local antibiotic concentrations 10-115 times higher than systemic administration while using only a fraction of the total drug amount, potentially minimizing systemic exposure and associated side effects. Clinical Development Progress and Regulatory Recognition The clinical development program for D-PLEX100 has demonstrated encouraging signals across multiple surgical contexts. In Phase 2 abdominal surgery trials, D-PLEX100 plus standard of care achieved a statistically significant 59% reduction in the primary endpoint compared to standard of care alone (p=0.0086). Perhaps more notably, the treatment group experienced zero deaths compared to five in the control arm within 60 days post-surgery. The pivotal SHIELD I Phase 3 trial, while not meeting its primary endpoint in the full intent-to-treat population, revealed compelling efficacy in a pre-specified subgroup analysis. Among patients with large surgical incisions (>20 cm), D-PLEX100 demonstrated a statistically significant 54% reduction in the composite primary endpoint of SSIs, reinterventions, and mortality (p=0.0032). This finding directly informed the design of the ongoing SHIELD II trial, which focuses specifically on this higher-risk patient FDA's regulatory designations reflect recognition of D-PLEX100's potential significance. Breakthrough Therapy designation is reserved for drugs that demonstrate substantial improvement over existing treatments for serious conditions. Fast Track designation facilitates more frequent FDA communications and potentially accelerated review timelines. The QIDP designation provides additional market exclusivity incentives for addressing antimicrobial resistance challenges. SHIELD II: A Potentially Definitive Study The ongoing SHIELD II Phase 3 trial represents a carefully designed study incorporating lessons learned from SHIELD I. Following an independent Data Safety Monitoring Board's review of unblinded efficacy data from the first 430 enrolled patients, the board recommended concluding the study at 800 patients—the lowest sample size reassessment option available. This recommendation, while requiring additional enrollment beyond the initially planned 624 patients, may suggest positive efficacy trends in the analyzed interim data. The study's multinational design spans approximately 60 centers across the United States, Europe, and Israel, enhancing the generalizability of results across different healthcare settings and patient populations. The primary endpoint focuses on a composite of SSI events, reinterventions, and mortality within 30 days post-surgery, as adjudicated by an independent committee. Broader Industry ImplicationsSuccess of D-PLEX100 could catalyze broader adoption of localized drug delivery approaches in surgical settings. The technology's platform nature suggests potential applications beyond infection prevention, including localized chemotherapy delivery through the company's OncoPLEX program, currently in preclinical development for solid tumor treatment. The substantial market opportunity—with approximately 12 million eligible procedures annually in the US and 8 million in Europe—underscores the potential healthcare impact. PolyPid has already secured European commercialization rights through a partnership with Advanz Pharma, valued at up to $115 million plus royalties, while advancing discussions for US market partnerships. Conclusion As the pharmaceutical industry grapples with antimicrobial resistance and healthcare systems seek cost-effective solutions to persistent clinical challenges, D-PLEX100's approaching data readout represents a potentially significant milestone. The convergence of compelling preclinical and early clinical data, regulatory recognition, and substantial unmet medical need positions this development as one to monitor closely in the evolving landscape of surgical infection News Highlight from PolyPid: PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections >> Click here to Subscribe for more updates like this or go to * Legal Disclaimer & Disclosure: Nothing in this report constitutes medical, financial or any form professional or licensedadvice. This report is published by 'PESG Research', a digital promotional content brand who's operators are compensated to provide digestable and favorabel coverage of companies. This report contains and is a form of paid promotional content or advertising for PolyPid Ltd and was produced as part of the fee's they pay PESG's operators, Arx Advisory Ltd. This report has not been reviewed or approved by PolyPId prior to publication and it does not represent an official communication from PolyPid. The operators of PESG Research received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from PolyPid as part of an ongoing agreement starting May 1, 2025 in return for distribution and promotional coverage services, and receive additional monthly compensation for non promotional unrelated data and advisory services on top of that. Please review the full disclaimers and compensation disclosures here for further details: Readers are advised to refer to the official materials of the company aforementioned. The report should not be treated as objective.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store